Establishment Labs Holdings Inc. announced that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Peter Caldini to become Interim CEO effective March 1, 2025.

Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active advisor to the Company, working with the plastic surgeon community to expand the breast aesthetics and reconstruction markets. He will continue to support the development and launch of next generation technologies and will continue as an industry advocate for keeping safety, innovation, and women?s choice at the forefront of the aesthetics industry. Peter Caldini joined Establishment Labs as President in 2024.

Previously, he served as the Chief Executive Officer and Director of Acreage Holdings Inc. from 2020 to 2023 and of Bespoke Capital Acquisition Corp. from 2019 to 2020. From 2015 to 2019, Mr. Caldini worked at Pfizer Consumer Healthcare where he was the Regional President for North America and prior to that role, Regional President of EMEA.

He worked at Bayer Consumer Healthcare from 2009 to 2014 where he held several roles of increasing responsibility, including Head of Emerging Markets, GM China, and Head of the Nutritionals Strategic Business Unit. Mr. Caldini received his undergraduate degree from Boston University, his MBA from Northeastern University, and a Master?s in International Economics and Management from SDA Bocconi.